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RNA quality controlRecent studies from independent laboratories have decisively disclosed the identity of the long-
sought 3–50 RNA exonuclease that trims posttranscriptionally the oligouridine tail of U6, which is
the small catalytic non-coding RNA promoting premRNA splicing within the spliceosome. This exo-
nuclease, dubbed Mpn1 or Usb1, is a highly conserved enzyme that speciﬁcally removes uridines
from the 30 end of U6, and directly generates terminal 20,30 cyclic phosphate groups. Mutations in
the human gene encoding hMpn1 have been reported in patients diagnosed with the rare genoder-
matosis Clericuzio-type poikiloderma with neutropenia (PN). Mpn1-associated functions in U6
small nuclear RNA posttranscriptional regulation suggest the existence of sophisticated cellular
pathways involved in surveillance and stabilization of U6. In this light, PN pathology might turn
out to be a consequence of disturbed quality control of RNAs involved in crucial biological events.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.Clericuzio-type poikiloderma with neutropenia (PN) is an auto-
somal-recessive hereditary disorder characterized by a papular
erythematous rash of the limbs and face during the ﬁrst year of
life; it typically evolves into diffuse poikiloderma and pachyo-
nychia, especially of the toenails. PN is also characterized by
chronic neutropenia and bone marrow abnormalities associated
with infection of the respiratory system and, eventually, myelodys-
plasia and risk of leukemic transformation. Rarely, PN is also asso-
ciated with squamous cell carcinoma [1–11]. The actual number of
reported patients is quite limited, mostly because several PN pa-
tients have been previously misdiagnosed with dyskeratosis con-
genita or Rothmund–Thomson syndrome as a result of the large
overlap of the clinical manifestations of these syndromes [7,10].
The screening of dyskeratosis congenita and Rothmund–Thomson
patients of thus far unknown genetic origin should expand the
number of reported PN cases in the near future. All PN patients
bear mutations in the gene C16orf57, also named hMPN1 (for ‘Mu-
tated in PN 1’ [12] or USB1 (for ‘U Six Biogenesis 1’ [13], which en-
codes a 265-amino-acid protein, herein referred to as hMpn1 [5].
Mutations in hMPN1 were ﬁrst associated with PN in 2010 [9],
and, to date, 19 different mutations within the gene have been
identiﬁed. All these mutations are expected to produce abruptly
truncated and therefore non-functional proteins [5]. Still, themolecular function of hMpn1 has remained elusive until 2012,
when our laboratory and two other groups reported on it [12–14].
Mpn1 orthologs are present in different eukaryotes, including
yeasts, plants, ﬂies, and mammals and, based on sequence struc-
ture predictions, they have been postulated to belong to the 2H
phosphodiesterase superfamily found in bacteria, archaea, and
eukaryotes [5,15]. This superfamily comprises different families
of RNA-modifying enzymes involved in a variety of cellular pro-
cesses, including bacterial 20–50 RNA ligases, fungal RNA ligases,
plant and yeast 10,20 cyclic nucleotide phosphodiesterases, and
mammalian 20,30 cyclic nucleotide phosphodiesterases [5,15].
Two catalytically active tetrapeptide motifs (H-X-T/S-X, where X
is a hydrophobic residue) are found in all 2H phosphodiesterase
superfamily members, and they correspond to H120/S122 and
H208/S210 in hMpn1, to H109/S111 and H199/S201 in the ﬁssion
yeast Schizosaccharomyces pombe (S. pombe) Mpn1 and to H133/
S135 and H231/S233 in the budding yeast Saccharomyces cerevisiae
(S. cerevisiae) Usb1 [5,15]. Recently, the crystal structure of hMpn1
has been resolved at 1.1 Å, unambiguously assigning it to the 2H
phosphodiesterase superfamily. The protein comprises two juxta-
posed lobes separated by a central groove, which exposes an active
site containing the two tetrapeptide motifs [14].
By using a combination of biochemistry, cell biology, and
molecular biology and applying it to both human and ﬁssion yeast
cells, we have demonstrated that Mpn1 is a novel 30–50 RNA exonu-
clease that speciﬁcally processes the evolutionarily conserved
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core component of the active spliceosome, the large cellular
machinery that converts premature messenger RNA (pre-mRNA)
molecules into mature mRNAs. U6 is approximately 100 bases in
length and is produced by RNA polymerase III (RNAPIII)-mediated
transcription [16,17]. The genomic sequence of U6 gene terminates
with a short stretch of thymines (ﬁve to six thymines in transcrip-
tionally active U6 genes in humans and nine thymines in the only
U6 gene of ﬁssion yeast), which comprise the canonical termina-
tion sequence for RNAPIII transcription 50-TTTT-30 [18]. Newly
transcribed U6 contains four template 30 end uridines [19–21],
yet at the transcriptome level, U6 molecules are largely heteroge-
neous in length as a result of extensive posttranscriptional modiﬁ-
cation of U6 30 termini. In both humans and ﬁssion yeasts,
approximately 90% of cellular U6 molecules contain a 30 oligouri-
dine (oligo(U)) tail comprising four template Us plus a ﬁfth non-
template U blocked by a 20,30 cyclic phosphate end group (>p).
The remaining 10% can contain 30 oligo(U) stretches up to 20 nucle-
otides long and terminating with a cis 20,30-diol end group (–OH)
[21–23]. In S. cerevisiae, a slightly different situation is observed
with the large majority of U6 terminating with a 30 or 20 single
phosphate group, and the remaining U6 terminating with an –OH
group [13,23]. Although not formally demonstrated, it is possible
that the single phosphate moiety present at the 30 end of the
majority of budding yeast U6 molecules derive from hydrolysis
of one of the two phosphate bonds within a >p group through
20,30 cyclic nucleotide phosphodiesterase activity. The dynamic
balance between the two major forms of U6 terminating with >p
or –OH groups is achieved through two counteracting enzymatic
activities that elongate and trim U6 oligo(U) tails [24–26]. The en-
zyme elongating the U6 30 end is TUTase, a non-canonical poly(A)
polymerase that oligouridylylates U6 upon transcription. The
TUTase polypeptide has been isolated in humans, while it
remains to be identiﬁed in S. pombe[27]. The existence of a
TUTase-antagonist enzyme that is capable of trimming U6 oligo(U)
tails has been known for a long time [26], but it is only with our
recent work that it has been identiﬁed as Mpn1 [12–14].
Consistent with the U6 trimming activity associated with Mpn1,
mpn1D ﬁssion yeasts and human cells established from different
PN patients carry U6 molecules with oligo(U) tails comprising
more than ﬁve uridines and devoid of any terminal phosphate
group [12,14]. This defect is rescued by ectopic expression of intact
Mpn1 proteins, but not by Mpn1 variants carrying histidine-to-ala-
nine substitutions within their tetrapeptide motifs, conﬁrming that
these sequences are essential for Mpn1 catalytic activity [12] and
our unpublished observations]. In vitro, puriﬁed hMpn1 is able to
trim long oligo(U) tails at the 30 end of U6-like RNA oligonucleo-
tides, generating shorter oligo(U) tails with ﬁve uridines, the last
of which contains a >p group [12,14]. Oligoadenosine tails at the
30 end of U6-like RNA oligonucleotides can also be processed by
Mpn1 in vitro [14]. Similar to what observed in vivo, recombinant
tetrapeptide motif-mutant hMpn1 is catalytically inactive [12,14].
According to these data, the lack of Mpn1 activity is sufﬁcient to
explain all molecular defects accruing on U6 molecules in Mpn1-
deﬁcient cells (i.e., longer oligo(U) tails and the lack of a >p group).
In human and yeast Mpn1 mutants, aberrant 30-end processing
coincides with a sharp decrease in U6 stability, as shown by half-
life measurements [12,13]. Intriguingly, the shorter half-life of U6
leads to lower U6 cellular levels only in yeast cells, where one
U6 gene is present. In contrast, no decrease in U6 levels has been
detected in human PN cells [12], possibly because in humans mul-
tiple U6 genes are present and their regulated transcription could
eventually compensate for the lower stability of the transcript
[28]. The diminished levels of U6 in mpn1D ﬁssion yeasts leads
to reduced steady-state levels of spliceosomal U4/U6-di-snRNPs
and a generalized pre-mRNA splicing defect that induces globalaccumulation of intron-containing mRNA [12]. Stable expression
of one extra copy of the U6 gene in mpn1D cells restores U6 levels
to those measured in wild-type cells and completely reverts the
splicing defects associated with mpn1 +deletion, indicating that
U6 levels are limiting in these cells [12]. Contrarily to budding
yeast where mpn1 deletion is lethal [13], mpn1D S. pombe cells
are alive although they proliferate more slowly than wild-type
cells in standard conditions, and this phenotype is exacerbated
when yeasts are grown in the cold. Moreover, mpn1D cells have
shorter telomeres and increased cellular levels of telomeric tran-
scripts, as compared to wild-type strains [12]. As with the splicing
defects, all these aberrations are reverted by U6 ectopic expression,
suggesting a correlation between splicing inefﬁciency and prolifer-
ation potential at low temperature, telomere length regulation, and
transcription of chromosome ends [12]. In other words, it is likely
that pre-mRNAs coding for proteins involved in low temperature
tolerance and telomere metabolism are inefﬁciently spliced in
the mutant.
In contrast to what is observed in yeast, next-generation
sequencing of the entire poly(A)+ transcriptome of cells from PN
patients revealed that pre-mRNA splicing ensues normally
[12,14], thus suggesting that PN manifestation might not derive
from generalized pre-mRNA splicing defects. Still, we have not dis-
missed the possibility that splicing could occur inefﬁciently at the
organismal level only in those tissues more dramatically affected
by the disease, such as neutrophil precursors in the bone marrow
or keratinocytes. An animal model for PN appears to be necessary
at this point to directly test this hypothesis. An alternative and not
mutually exclusive hypothesis is that U6 snRNA, at least in human
cells, is not the only substrate for hMpn1, and deregulation of
hMpn1 substrates other than U6 could be the cause of PN. Given
the in vitro preference of Mpn1 for RNA molecules that terminate
with six or more uridines [12,14], several RNAPIII transcripts could
represent suitable candidates as long as they are also modiﬁed by
oligo(U) addition postranscriptionally. Recently, protocols have
been published to produce complementary DNA libraries from
RNA terminating with >p groups and suitable for next-generation
sequencing. These protocols rely on the utilization of RNA ligases
that are speciﬁcally able to ligate >p-containing 30 ends, such as
Arabidopsis thaliana transfer RNA ligase [29]. Sequencing of the
>p-containing transcriptome of cells from PN patients will cer-
tainly help clarify the identity of hMpn1 substrates.
Regardless of the molecular basis leading to PN development,
the discovery of Mpn1’s function in U6 posttranscriptional regula-
tion and stabilization raises a number of intriguing questions. First,
the fact that oligo(U) tails with a terminal 20,30 cyclic phosphate
render U6 molecules more stable suggests a role for this chemical
modiﬁcation in RNA stability. How might this work? The RNA
machinery degrading U6 molecules that have not been processed
by Mpn1 and are therefore devoid of >p groups has not yet been
carefully analyzed. It has been reported in several studies that
the nuclear exosome component Rrp6 [30] associates in vivo with
U6 RNA in budding yeast and that cells deleted for rrp6 accumulate
U6 molecules with long poly(A) tails [31,32]. Similarly, a fraction of
Drosophila U6 snRNA is 30 polyadenylated [33]. Although polyaden-
ylated U6 is not detected in Mpn1-deﬁcient human and yeast cells
[14] and our unpublished observations] it is still possible that, in
the absence of Mpn1, U6 molecules are quickly polyadenylated
and immediately degraded by Rrp6. Polyadenylation is executed
by the non-canonical poly(A) polymerase Trf4, which adds long oli-
go(A) tails to RNA 30 ends containing a 30 –OH group [30]. The pres-
ence of a >p group could hinder Trf4-mediated polyadenylation at
the 30 end of an RNA molecule. A >p group would therefore repre-
sent a chemical mark promoting the stability of U6 or other RNA
molecules by chemically preventing the action of Trf4. Deep
sequencing of U6 30 ends from PN patients has revealed an
Fig. 1. Speculative model depicting Mpn1-associated functions in quality control and stabilization of U6 snRNA. Freshly transcribed U6 molecules are uridylylated by TUTase
and associate with the spliceosome for a ﬁrst round of splicing. These molecules comprise long oligo(U) tails terminating with cis 20 ,30-diol groups (–OH; green circles).
Possibly during splicing, the catalytic activity of U6 undergoes a quality check. In normal conditions, most U6 molecules pass the quality control procedure (large arrow on the
left; green quality mark) and their oligo(U) tails are trimmed by Mpn1 and blocked by the introduction of terminal 20 ,30 cyclic phosphate groups (>p; pink circles). Mpn1-
processed U6 molecules remain stable in the cell and can be recycled with the aid of the Lsm2–8 complex (in orange) for new rounds of splicing. The few splicing-
incompetent U6 molecules that fail to pass the quality check (thin arrow on the right; red quality mark) are not trimmed by Mpn1 and directly eliminated from the cell by
RNA degradation machineries still to be identiﬁed. See text for further details.
1860 V. Shchepachev, C.M. Azzalin / FEBS Letters 587 (2013) 1858–1862accumulation of molecules terminating with 1–4 adenine residues
[14]. Similarly, a small fraction of U6 molecules from HeLa cells
and lymphoblasts from healthy individuals contain a posttran-
scriptionally added adenylic acid residue at their 30 end [14,34],
suggesting that, indeed, Mpn1-mediated trimming of U6 would
prevent oligoadenylation and possibly degradation. It has not yet
been demonstrated what enzymatic activity accomplishes oligoa-
denylation of U6 when Mpn1 does not process it; nevertheless,
as proposed by Hilcenko and colleagues, this modiﬁcation could
be directly imposed again by Trf4 [14].
U6 stabilization upon Mpn1-mediated trimming and >p group
generation could also be achieved by promoting U6 association
with cellular factors that are capable of offsetting the degradation
mechanisms. In vitro, the presence of a terminal >p group on U6
oligonucleotides enhances their afﬁnity for the nuclear Sm-like
Lsm2–8 ring complex [35]. It is conceivable that binding of the
Lsm2–8 complex stabilizes U6 by hiding its 30 end from degrada-
tion machines, such as the nuclear exosome. Supporting this
hypothesis, independent yeast strains functionally inactivated for
each component of the Lsm2–8 complex display lower U6 cellular
levels [36], a phenotype that is reminiscent of mpn1+deletion. To
date, testing of this hypothesis in vivo has been impeded by the
fact that the identity of the nuclease generating the >p in U6 was
unknown. Now that this nuclease has been identiﬁed, it is possible
to directly assay the impact of the lack of a >p group on U6 bindingto Lsms in the cell by analyzing U6/Lsm interactions in mpn1D
yeasts and in PN cells.
A fundamental question in Mpn1 biology remains to be ad-
dressed: what is the molecular relevance of the cellular pathways
that rely on Mpn1 activity? Is Mpn1 simply a stabilization factor
for U6? Or is a more complex mechanism hidden behind the activ-
ity of Mpn1? As already mentioned, accumulation of U6 molecules
with long poly(A) tails introduced by Trf4 have has been reported
in budding yeasts deleted for rrp6, but not in human PN cells or in
mpn1D ﬁssion yeasts [14,32] and our unpublished observations].
Therefore, it seems that one general mechanism of U6 degradation
based on Trf4 and the nuclear exosome, and possibly not con-
nected to Mpn1, is operating in the cell. If this stands true, it should
then be asked why evolutionarily distant eukaryotes would devel-
op a second pathway of degradation that appears to involve oligoa-
denylation of U6 and that is counteracted by Mpn1. Perhaps this
second pathway is more sophisticated than general RNA degrada-
tion executed by the cells as a means of maintaining a balance be-
tween newly synthesized and degraded RNAs. The key to
understanding this riddle might be the fact that U6 is a catalytic
RNA and that the large majority of cellular U6 is utilized several
times in successive cycles of splicing in a process known as U6
recycling [37,38]. While on one side the possibility of recycling
the same RNA molecule for multiple catalysis events is energeti-
cally favorable for a cell, a mechanism should exist to allow cells
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satisfactory and therefore decide to store this molecule for suc-
cessive splicing cycles. It is plausible that cells have evolved a
quality control mechanism that tests the functionality of each
and every U6 molecule and that then directs catalytically inactive
or otherwise splicing-incompetent U6 molecules toward degrada-
tion. The existence of such a quality control mechanism seems to
be necessary to avoid the harmful accumulation of dysfunctional
U6 in the cell in particular when cells have experienced external
insults that could introduce mutations in RNA molecules. A few
reported experiments support the idea of a U6-speciﬁc surveil-
lance pathway. Indeed, several U6 mutant alleles, unable to cata-
lyze splicing, have reduced steady-state levels as compared to
catalytically active versions when expressed ectopically in bud-
ding yeasts [39].
We speculate that Mpn1 could function as a downstream
effector for U6 quality control. As depicted in the model shown
in Fig. 1, we propose that, upon transcription and TUTase-medi-
ated uridylylation U6 molecules enter a ﬁrst cycle of splicing with
long oligo(U) tails terminating with an –OH group. At this point
the catalytic activity of U6 is checked, using as readout its ability
to promote splicing properly. In the majority of cases, new U6
molecules should pass the quality control procedure, and this
outcome would be communicated to Mpn1, which would then
trim the U6 oligo(U) tail and introduce a >p group, thereby avert-
ing U6 degradation (Fig. 1). In the event that a U6 molecule fails
the quality control check, Mpn1 would then be prevented from
processing it and access would be granted to the RNA degradation
machinery, with consequent elimination of dysfunctional U6 from
the cell (Fig. 1). In this scenario, in Mpn1-deﬁcient cells, all U6
molecules would be considered dysfunctional and would there-
fore be directed immediately toward degradation upon comple-
tion of the ﬁrst round of splicing. A direct consequence of this
model is that Mpn1-deﬁcient cells would be unable to recycle
U6. This hypothesis is directly testable via in vitro splicing assays
using splicing extracts prepared from human PN and yeast
mpn1D cells.
It will also be of interest to understand how Mpn1 is recruited
to U6 molecules, possibly right after U6 has passed the quality con-
trol test. We have shown that hMpn1 associates with the NineTeen
Complex (NTC), a multiprotein complex that is essential for the
maintenance of spliceosome integrity and efﬁcient splicing
[12,40]. High-throughput studies in budding yeasts and ﬂies have
further conﬁrmed direct interactions between Mpn1 and Prp19, a
key NTC member, indicating that such interaction is a strong evo-
lutionarily conserved feature of Mnp1 [41–44]. We suggest that
Mpn1 is recruited to active spliceosomes by the NTC upon splicing
execution and, possibly, quality control. Interestingly, the yeast
NTC has also been shown to be involved in U6 stabilization and
recycling, further strengthening the connection between these pro-
cesses and Mpn1 [37,45].
In conclusion, Mpn1 and its associated functions seem to be
the building blocks of a new puzzle in RNA biology. We believe
that complete characterization of the RNA degradation complexes
counteracted by Mpn1, as well as of the putative surveillance of
U6 and perhaps other catalytic RNAs, will contribute to unravel-
ing the complex means used by cells to properly perform essen-
tial cellular reactions such as pre-mRNA splicing. In the long
term, we are conﬁdent that understanding the details of Mpn1-
associated functions will help to clarify how PN is established
and whether it can be considered as a disorder deriving from mis-
regulated quality control of diverse catalytic RNAs. A detailed
analysis of speciﬁc RNA metabolism pathways affected by Mpn1
loss of function in different tissues from PN patients or model
animals should help in the development of possible therapeutic
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